Uncovering the System Vulnerability and Criticality of Human Brain Under Dynamical Neuropathological Events in Alzheimer's Disease.

Background: Despite the striking efforts in investigating neurobiological factors behind the acquisition of amyloid-β (A), protein tau (T), and neurodegeneration ([N]) biomarkers, the mechanistic pathways of how AT[N] biomarkers spreading throughout the brain remain elusive. Objective: To disentangle the massive heterogeneities in Alzheimer’s disease (AD) progressions and identify vulnerable/critical brain regions to AD pathology. Methods: In this work, we characterized the interaction of AT[N] biomarkers and their propagation across brain networks using a novel bistable reaction-diffusion model, which allows us to establish a new systems biology underpinning of AD progression. We applied our model to large-scale longitudinal neuroimages from the ADNI database and studied the systematic vulnerability and criticality of brains. Results: Our model yields long term prediction that is statistically significant linear correlated with temporal imaging data, produces clinically consistent risk prediction, and captures the Braak-like spreading pattern of AT[N] biomarkers in AD development. Conclusions: Our major findings include (i) tau is a stronger indicator of regional risk compared to amyloid, (ii) temporal lobe exhibits higher vulnerability to AD-related pathologies, (iii) proposed critical brain regions outperform hub nodes in transmitting disease factors across the brain, and (iv) comparing the spread of neuropathological burdens caused by amyloid-β and tau diffusions, disruption of metabolic balance is the most determinant factor contributing to the initiation and progression of AD.

[1]  Guorong Wu,et al.  Analyzing The Spatiotemporal Interaction And Propagation Of Atn Biomarkers In Alzheimer’s Disease Using Longitudinal Neuroimaging Data , 2021, 2021 IEEE 18th International Symposium on Biomedical Imaging (ISBI).

[2]  Guorong Wu,et al.  A Network-Guided Reaction-Diffusion Model of AT[N] Biomarkers in Alzheimer’s Disease , 2020, 2020 IEEE 20th International Conference on Bioinformatics and Bioengineering (BIBE).

[3]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[4]  Guorong Wu,et al.  Characterizing the Propagation Pattern of Neurodegeneration in Alzheimer's Disease by Longitudinal Network Analysis , 2020, 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI).

[5]  Elizabeth C Mormino,et al.  Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention , 2020, Brain communications.

[6]  O. Hansson,et al.  Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.

[7]  Sang Won Seo,et al.  Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease , 2019, Brain : a journal of neurology.

[8]  Feng Zhou,et al.  Graph Convolutional Network Analysis for Mild Cognitive Impairment Prediction , 2019, 2019 IEEE 16th International Symposium on Biomedical Imaging (ISBI 2019).

[9]  Alan C. Evans,et al.  Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease , 2019, bioRxiv.

[10]  E. Kuhl,et al.  Prion-like spreading of Alzheimer’s disease within the brain’s connectome , 2019, bioRxiv.

[11]  J. Morris,et al.  Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative , 2018, Alzheimer's & Dementia.

[12]  Prashanthi Vemuri,et al.  Resistance vs resilience to Alzheimer disease , 2018, Neurology.

[13]  L. Tan,et al.  Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy , 2018, Neurotoxicity Research.

[14]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[15]  Corinne E. Fischer,et al.  Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease , 2017, JAMA psychiatry.

[16]  Yue-Ming Li,et al.  The role of astrocytes in amyloid production and Alzheimer's disease , 2017, Open Biology.

[17]  M. O’Sullivan,et al.  Association of imaging abnormalities of the subcallosal septal area with Alzheimer's disease and mild cognitive impairment , 2017, Clinical radiology.

[18]  Andrea Tosin,et al.  Well-Posedness of a Mathematical Model for Alzheimer's Disease , 2017, SIAM J. Math. Anal..

[19]  Karsten Melcher,et al.  Amyloid beta: structure, biology and structure-based therapeutic development , 2017, Acta Pharmacologica Sinica.

[20]  F De Vico Fallani,et al.  Loss of brain inter-frequency hubs in Alzheimer's disease , 2016, Scientific Reports.

[21]  Timothy J. Hohman,et al.  Asymptomatic Alzheimer disease , 2016, Neurology.

[22]  M. Diamond,et al.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo , 2016, Neuron.

[23]  Avner Friedman,et al.  Mathematical model on Alzheimer’s disease , 2016, BMC Systems Biology.

[24]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[25]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[26]  Ayman El-Baz,et al.  Alzheimer's disease diagnostics by adaptation of 3D convolutional network , 2016, 2016 IEEE International Conference on Image Processing (ICIP).

[27]  J. Abrahams,et al.  Cross-interactions between the Alzheimer Disease Amyloid-β Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis* , 2016, The Journal of Biological Chemistry.

[28]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[29]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[30]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[31]  Wei Chen,et al.  Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer’s disease patients with depression: a 1H magnetic resonance spectroscopy study , 2015, BMC Psychiatry.

[32]  D. Holtzman,et al.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.

[33]  Andrea Tosin,et al.  Alzheimer's disease: a mathematical model for onset and progression. , 2015, Mathematical medicine and biology : a journal of the IMA.

[34]  Michael Weiner,et al.  Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease. , 2015, Cell reports.

[35]  Alan C. Evans,et al.  Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders , 2014, PLoS Comput. Biol..

[36]  Marina Boccardi,et al.  Medial temporal atrophy in early and late-onset Alzheimer's disease , 2014, Neurobiology of Aging.

[37]  Bradley T. Hyman,et al.  The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease , 2014, Neuron.

[38]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[39]  Lewis H Kuller,et al.  In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects , 2013, Annals of neurology.

[40]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[41]  Alan C. Evans,et al.  Convergence and divergence of thickness correlations with diffusion connections across the human cerebral cortex , 2012, NeuroImage.

[42]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[43]  Anders M. Dale,et al.  Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature , 2010, NeuroImage.

[44]  R. V. Van Heertum,et al.  Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls , 2010, Journal of geriatric psychiatry and neurology.

[45]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[46]  E. Masliah,et al.  Molecular mechanisms of neurodegeneration in Alzheimer's disease. , 2010, Human molecular genetics.

[47]  R. Maccioni,et al.  The revitalized tau hypothesis on Alzheimer's disease. , 2010, Archives of medical research.

[48]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[49]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[50]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[51]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[52]  M. Maurin,et al.  REVIEW ARTICLE doi: 10.1111/j.1472-8206.2008.00633.x The Hill equation: a review of its capabilities in pharmacological modelling , 2008 .

[53]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[54]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[55]  Kim N. Green,et al.  Intracellular amyloid-β in Alzheimer's disease , 2007, Nature Reviews Neuroscience.

[56]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[57]  Alan C. Evans,et al.  Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. , 2004, Cerebral cortex.

[58]  Laura Fratiglioni,et al.  Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. , 2004, American journal of epidemiology.

[59]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[60]  L. Barbeito,et al.  The molecular bases of Alzheimer's disease and other neurodegenerative disorders. , 2001, Archives of medical research.

[61]  D. Holtzman,et al.  Clearance of amyloid β-peptide from brain: transport or metabolism? , 2000, Nature Medicine.

[62]  A. Convit,et al.  Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease☆ , 2000, Neurobiology of Aging.

[63]  D. Goldberg,et al.  BOA: the Bayesian optimization algorithm , 1999 .

[64]  L A Beckett,et al.  Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. , 1997, Archives of neurology.

[65]  James N. Weiss The Hill equation revisited: uses and misuses , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  M. Goedert Tau protein and the neurofibrillary pathology of Alzheimer's disease , 1993, Trends in Neurosciences.

[67]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[68]  Guorong Wu,et al.  A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[69]  Stuart Maudsley,et al.  Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. , 2012, Current Alzheimer research.

[70]  F. Schmitt,et al.  Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[71]  Tamara G. Kolda,et al.  Optimization by Direct Search: New Perspectives on Some Classical and Modern Methods , 2003, SIAM Rev..

[72]  D. E. Goldberg,et al.  Genetic Algorithms in Search , 1989 .